Synlogic
Yahoo Finance • 5 months ago
Synlogic files $150M mixed securities shelf
* Synlogic (NASDAQ:SYBX [https://seekingalpha.com/symbol/SYBX]) filed $150M mixed securities shelf. * Filing MORE ON SYNLOGIC * Financial information for Synlogic [https://seekingalpha.com/symbol/SYBX/income-statement] ... Full story
Yahoo Finance • 2 years ago
Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ...
Synlogic Inc (NASDAQ:SYBX) announced an extended cash runway into the first half of 2025 following a $21.0 million public offering and a $2.5 million milestone payment from Roche. The company's pivotal Synpheny-3 trial in PKU is on track,... Full story
Yahoo Finance • 2 years ago
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enro... Full story
Yahoo Finance • 2 years ago
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announc... Full story
Yahoo Finance • 2 years ago
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today a... Full story
Yahoo Finance • 2 years ago
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today... Full story
Yahoo Finance • 2 years ago
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today... Full story
Yahoo Finance • 2 years ago
Synlogic Announces Reverse Stock Split
CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today... Full story
Yahoo Finance • 2 years ago
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today... Full story
Yahoo Finance • 2 years ago
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
RESEARCH TRIANGLE PARK, N.C., July 11, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology compan... Full story
Yahoo Finance • 2 years ago
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today a... Full story
Yahoo Finance • 2 years ago
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
The World Health Organization has approved “labafenogene marselecobac” Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria community CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Synlogic... Full story
Yahoo Finance • 3 years ago
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today a... Full story
Yahoo Finance • 3 years ago
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB193... Full story
Yahoo Finance • 3 years ago
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan... Full story
Yahoo Finance • 3 years ago
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poste... Full story
Yahoo Finance • 3 years ago
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion... Full story
Yahoo Finance • 3 years ago
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the company’s Phase 2 Synpheny-1 study for pheny... Full story
Yahoo Finance • 3 years ago
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Execu... Full story
Yahoo Finance • 3 years ago
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), th... Full story
